Inimitable Imatinib: The range of targeted tumours expands to include T-cell lymphoma

Leukemia

Volumn 27, Issue 4, 2013, Pages 759-

  Turner, S D ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; EDITORIAL; HUMAN; IMMUNITY; LARGE CELL LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA;

ANTINEOPLASTIC AGENTS; BENZAMIDES; HUMANS; LYMPHOMA, T-CELL; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 84876149606     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.304     Document Type: Editorial

References (5)

1. Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol 2012; 83: 293-302.
2. Shami PJ, Deininger M. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 2012; 26: 214-224.
3. Gunby RH, Ahmed S, Sottocornola R, Gasser M, Redaelli S, Mologni L et al. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. J Med Chem 2006; 49: 5759-5768.
4. Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O et al. Identification of PDGFR blockade as a rational and highly effective therapy for NPM-ALK driven lymphomas. Nature Medicine 2012; e-pub ahead of print 14 October 2012; doi:10.1038/nm.2966.
5. Mussolin L, Damm-Welk C, Pillon M, Zimmermann M, Franceschetto G, Pulford K et al. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia 2012; e-pub ahead of print 21 August 2012; doi:10.1038/leu.2012.205.